The role of different types of MET mutation in lung cancer could demand a rethink of treatments.
“Right to Try” legislation may have compassion at its heart, but it does not do enough to ensure patient protection.
Looking at miRNA expression levels may improve our ability to subtype bladder cancers and provide the most appropriate and effective treatment
MALDI and a SpiderMass device could save valuable surgery time
Better lung cancer treatment through biomarkers
Pier Paolo Pandolfi
A giant of leukemia research and treatment discusses his career
How ATR-FTIR spectroscopy could lead to less invasive cancer prescreening
What characteristics make a cancer therapy more likely to effectively treat disease?
Testing the whole population of women for breast/ovarian cancers mat be more cost-effective than current methods
Obi Griffith and Heidi Rehm
It's important to research relevant academic papers, but it's equally important to make sure it's still relevant
Send me the latest from The Translational Scientist.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.